Sotatercept safe and effective across cardiac index groups

PHA Canada
Dec 18, 2024
1 min read

Cardiac index (CI) assesses the output of someone's heart based on their size. It measures heart function relative to the person's size (litres per minute per square metre), instead of just cardiac output (litres per minute). A study looked at data from both the PULSAR and STELLAR trials for sotatercept and found that, compared to placebo, sotatercept improved 6-minute walk distance consistently and was equally safe for people in all cardiac index groups.

Click here to read the paper in the Journal of Heart and Lung Transplantation

Recent Posts

Promising results for drug candidate CS1

This press release reports that over the 12 months of their Expanded Access Program enrolling ten patients, the majority of patients with pulmonary arterial hypertension who completed treatment with d

Using sotatercept off-label in children

Clinical trials for sotatercept didn't include children, so any pediatric use is off-label. This study, conducted at one children's hospital in San Diego, evaluated sotatercept in 7 pediatric patients

Phase 1 trial of treprostinil prodrug patch succeeds

A 9-participant phase 1 clinical trial used a patch to deliver a prodrug of treprostinil (a prodrug is something that is metabolized into the drug in question inside the body). Each participant wore a

Comments